Aminologics Co.,Ltd.
Financials
Valuation Metrics
Aminologics Co.,Ltd.'s Market Cap is ₩899B. At end of 2025 it was ₩1067B. Ranked #1346 of 2,421 in KR market (top 56%), #750 of 1,640 on KOSDAQ (top 46%), #157 of 294 in Materials (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 89.88B KRW | KR#1,346/2,421 Sec#157/294 |
| Revenue | 26.16B KRW | KR#2,078/2,421 Sec#276/294 |
| Net Income | 3.16B KRW | KR#1,340/2,421 Sec#173/294 |
| Total Assets | 89.72B KRW | KR#1,865/2,421 Sec#255/294 |
| Net Assets | 58.43B KRW | KR#1,805/2,421 Sec#245/294 |
| Employees | 38 | KR#2,148/2,421 Sec#266/294 |
| Value | ||
| P/E | 28.45x | KR#1,294/2,421 Sec#173/294 |
| P/B | 1.54x | KR#1,784/2,421 Sec#261/294 |
| P/S | 3.44x | KR#2,037/2,421 Sec#281/294 |
| EV/EBITDA | 15.15x | KR#862/2,421 Sec#103/294 |
| Profitability | ||
| ROE | 5.41% | KR#1,053/2,421 Sec#106/294 |
| ROA | 3.52% | KR#959/2,421 Sec#103/294 |
| Op. Margin | 20.95% | KR#150/2,421 Sec#2/294 |
| Revenue Growth | 64.47% | KR#148/2,421 Sec#7/294 |
| Financial Health | ||
| Debt Ratio | 53.54% | KR#1,009/2,421 Sec#115/294 |
| Total Debt | 16.19B KRW | KR#1,464/2,421 Sec#219/294 |
| Cash | 23.08B KRW | KR#1,165/2,421 Sec#140/294 |
| Current Ratio | 2.28x | KR#763/2,421 Sec#79/294 |
| Net Debt/EBITDA | -1.26x | KR#327/2,421 Sec#38/294 |
| Performance | ||
| 1Y Return | -0.20% | KR#737/2,421 Sec#83/294 |
| 1M Return | -17.47% | KR#2,282/2,421 Sec#276/294 |
| From 52W High | -48.14% | KR#1,298/2,421 Sec#183/294 |
| 1Y MDD | -47.39% | KR#875/2,421 Sec#122/294 |
| Trading | ||
| Volume | 125,978 shares | KR#675/2,421 Sec#56/294 |
| Trading Value | 126.7M KRW | KR#1,454/2,421 Sec#158/294 |
| Foreign Own. | 2.20% | KR#1,556/2,421 Sec#183/294 |
| Per Share | ||
| EPS | 35 KRW | KR#1,517/2,421 Sec#201/294 |
| BPS | 654 KRW | KR#2,368/2,421 Sec#292/294 |
Company Info
Aminologics, established in 1997 and KOSDAQ listed in 2004, is a small and medium-sized venture enterprise. The company acquired the active pharmaceutical ingredient (API) business rights from Sam-O Pharmaceutical in 2015, supplying APIs for stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. Since 2009, Aminologics has been developing various products, including D-Serine, through its amino acid derivative business. Recognized for its quality by global customers, the company is actively engaged in research and development to capture the peptide new drug market, receiving new development requests. Aminologics is headquartered in Gangnam-gu, Seoul.